These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8960669)

  • 1. [The clinical significance of minimal residual disease of acute leukemia with t(4;11) (q21;q23)].
    Okamura T; Park YD; Inoue M; Yasui M; Ueno M; Endo C; Yagi K; Kawa K
    Rinsho Ketsueki; 1996 Nov; 37(11):1318-21. PubMed ID: 8960669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in MLL/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia.
    Hilden JM; Chen CS; Moore R; Frestedt J; Kersey JH
    Cancer Res; 1993 Sep; 53(17):3853-6. PubMed ID: 8358709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.
    Metzler M; Strissel PL; Strick R; Niemeyer C; Roettgers S; Borkhardt A; Harbott J; Ludwig WD; Stanulla M; Schrappe M; Reinhardt D; Creutzig U; Beck JD; Rascher W; Repp R; Langer T
    Genes Chromosomes Cancer; 2004 Nov; 41(3):291-6. PubMed ID: 15334554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
    Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
    Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical validation of a monochrome real-time multiplex assay for translocations in childhood acute lymphoblastic leukemia.
    Siraj AK; Ozbek U; Sazawal S; Sirma S; Timson G; Al-Nasser A; Bhargava M; El Solh H; Bhatia K; Gutiérrez MI
    Clin Cancer Res; 2002 Dec; 8(12):3832-40. PubMed ID: 12473597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.
    Hotfilder M; Röttgers S; Rosemann A; Schrauder A; Schrappe M; Pieters R; Jürgens H; Harbott J; Vormoor J
    Cancer Res; 2005 Feb; 65(4):1442-9. PubMed ID: 15735032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
    Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
    Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11).
    Griesinger F; Elfers H; Ludwig WD; Falk M; Rieder H; Harbott J; Lampert F; Heinze B; Hoelzer D; Thiel E
    Leukemia; 1994 Apr; 8(4):542-8. PubMed ID: 7908708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel t(4;11)(q21;q23) MLL-AF4 fusion transcript in infant leukemia.
    Abdelhaleem M; Yi Q; Beimnet K; Grant R
    Am J Hematol; 2007 Mar; 82(3):247. PubMed ID: 16924642
    [No Abstract]   [Full Text] [Related]  

  • 17. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
    Cazzaniga G; Gaipa G; Rossi V; Biondi A
    Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
    Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
    Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.